Clinical Trial Update: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

View source ↗

Summary

This clinical trial update reports the completion of an observational study of nivolumab plus ipilimumab in patients with previously unresectable malignant pleu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Groupe Francais De Pneumo-Cancerologie | Conditions: Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm | Status: COMPLETED